Recombinant Human DPP4 protein, hFc-Flag&Myc-tagged

• Cat.No.: DPP4-5879H
• Product Overview: Recombinant Human DPP4 protein(P27487)(29-766aa), fused with N-terminal hFc and Flag tag and C-terminal Myc tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: N-hFc-Flag&C-Myc
• Protein length: 29-766aa
• Form: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
• Molecular Mass: 109.7 kDa
• AASequence: NKGTDDATADSRKTYTLTDYLKNTY RLKLYSLRWISDHEYLYKQENNILV FNAEYGNSSVFLENSTFDEFGHSIN DYSISPDGQFILLEYNYVKQWRHSY TASYDIYDLNKRQLITEERIPNNTQ WVTWSPVGHKLAYVWNNDIYVKIEP NLPSYRITWTGKEDIIYNGITDWVY EEEVFSAYSALWWSPNGTFLAYAQF NDTEVPLIEYSFYSDESLQYPKTVR VPYPKAGAVNPTVKFFVVNTDSLSS VTNATSIQITAPASMLIGDHYLCDV TWATQERISLQWLRRIQNYSVMDIC DYDESSGRWNCLVARQHIEMSTTGW VGRFRPSEPHFTLDGNSFYKIISNE EGYRHICYFQIDKKDCTFITKGTWE VIGIEALTSDYLYYISNEYKGMPGG RNLYKIQLSDYTKVTCLSCELNPER CQYYSVSFSKEAKYYQLRCSGPGLP LYTLHSSVNDKGLRVLEDNSALDKM LQNVQMPSKKLDFIILNETKFWYQM ILPPHFDKSKKYPLLLDVYAGPCSQ KADTVFRLNWATYLASTENIIVASF DGRGSGYQGDKIMHAINRRLGTFEV EDQIEAARQFSKMGFVDNKRIAIWG WSYGGYVTSMVLGSGSGVFKCGIAV APVSRWEYYDSVYTERYMGLPTPED NLDHYRNSTVMSRAENFKQVEYLLI HGTADDNVHFQQSAQISKALVDVGV DFQAMWYTDEDHGIASSTAHQHIYT HMSHFIKQCFSLP
• Purity: Greater than 90% as determined by SDS-PAGE.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C.

Gene Information

• Gene Name: DPP4 dipeptidyl-peptidase 4 [ Homo sapiens ]
• Official Symbol: DPP4
• Synonyms: DPP4; dipeptidyl-peptidase 4; ADCP2, adenosine deaminase complexing protein 2 , CD26, dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); dipeptidyl peptidase 4; DPPIV; ADCP-2; DPP IV; dipeptidylpeptidase 4; dipeptidyl peptidase IV; T-cell activation antigen CD26; adenosine deaminase complexing protein 2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); CD26; ADABP; ADCP2; TP103
• Gene ID: 1803
• mRNA Refseq: NM_001935
• Protein Refseq: NP_001926
• MIM: 102720
• UniProt ID: P27487

Reviews

09/13/2019

Its purity and efficacy make it an ideal choice for precise and accurate analysis, allowing me to generate reliable results.

01/27/2019

By incorporating the DPP4 Protein into their studies, scientists can confidently conduct their research, ushering in groundbreaking discoveries and novel insights within their respective domains.

12/14/2016

Its exceptional purity and functionality make it an ideal choice for accurate and precise analysis, ensuring reliable and reproducible results.

Q&As

How does DPP4 relate to diabetes?

DPP4 plays a crucial role in glucose homeostasis by cleaving incretin hormones. In diabetes, inhibiting DPP4 can enhance the action of these hormones, promoting insulin release and lowering blood sugar levels.

Are there any side effects associated with DPP4 inhibitors?

Common side effects of DPP4 inhibitors include respiratory and urinary tract infections, headache, and nasopharyngitis. However, they are generally well-tolerated.

What clinical applications does DPP4 have in managing type 2 diabetes?

Inhibitors of DPP4 are used in the treatment of type 2 diabetes to improve glycemic control. They work by prolonging the activity of incretin hormones, such as GLP-1, which stimulate insulin secretion.

Can DPP4 inhibitors be used as a monotherapy for diabetes?

DPP4 inhibitors are often used as monotherapy or in combination with other antidiabetic medications to achieve optimal glycemic control.

How do DPP4 inhibitors differ from other diabetes medications?

DPP4 inhibitors work by enhancing the effects of incretin hormones, while other diabetes medications may act on insulin sensitivity, insulin release, or glucose absorption.